The Genito Urinary System and Sex Hormones market sales in South Korea showed significant variances from 2013 to 2023. By 2023, the sales stood at $18 per capita. The market experienced fluctuations with some notable year-on-year changes, such as a -4.65% dip in 2016, and high growth rates such as 12.82% in 2014 and 10.62% in 2021. The Compound Annual Growth Rate (CAGR) over the last five years averaged 3.85%, indicating steady growth despite the fluctuations.
Looking ahead, the forecasted period from 2024 to 2028 suggests a slower but steady growth with a forecasted CAGR of 2.36%, translating to a forecasted growth rate of 12.37% over five years. This suggests a continued but moderated demand for Genito Urinary System and Sex Hormone products.
Future trends to watch for:
- Technological advancements in medical treatments and pharmaceuticals
- Potential impacts of healthcare policies and regulations
- Demographic changes affecting demand, particularly aging populations
- Economic factors influencing healthcare spending
Latest reports
US Erectile Dysfunction Market Report- Q1 2025
The US Erectile Dysfunction (ED) market in Q1 2025 is navigating a challenging economic landscape marked by inflationary pressures, geopolitical tensions, and a...
South Korea Erectile Dysfunction Market Report- Q4 2024
The South Korean Erectile Dysfunction (ED) market in the fourth quarter of 2024 is characterized by evolving consumer preferences, technological innovations, and economic...
Spain Erectile Dysfunction Market Report- Q4 2024
The fourth quarter of 2024 presents a dynamic period for the Erectile Dysfunction (ED) market in Spain, marked by significant developments and emerging...
